12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BIT225: Phase II started

Biotron began an open-label, Thai Phase II trial to evaluate 300 mg BIT225 once daily on days 7 and 35 and twice daily on days 8-34 in combination...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >